Active CMOS biochip for electrochemical DNA assays

Peter M. Levine, Ping Gong, Rastislav Levicky, Kenneth L. Shepard

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

20 21The development of methods and technology to perform genome sequencing and genomic assays has enabled significant advances in biomedical research in the past and will have a profound impact on the areas of disease prevention, personalized medicine, and clinical diagnostics in the future [1]. Over the last two decades, enormous effort from the public and private sectors has been spent on “sequencing” the human genome; that is, determining the exact series of the approximately 6 billion nucleotide base pairs contained in the 46 chromosomes found in most human cells. Ever since drafts of the human genome were first published in 2001 by both the publicly funded International Human Genome Sequencing Consortium through the Human Genome Project (HGP) [2] and a team led by J. Craig Venter of the privately owned biotechnology company Celera Genomics [3], the cost of human genome sequencing has declined by many orders of magnitude due to the introduction of increasingly automatable methods and technology. In particular, shotgun sequencing approaches [4] involving dideoxy chain termination techniques and electrophoretic size separation (known as “Sanger sequencing,” after the individual who developed the technique [5]) have been replaced by massively parallel optical [6,7] and electronic [8] sequencing-by-synthesis platforms. These innovations have brought the cost of human genome sequencing down from US$3 billion, in the case of the HGP [9], to well under US$1 million [8]. Further technological developments will undoubtedly occur until one’s own genome can be sequenced for less than US$1000 [10].

Original languageEnglish (US)
Title of host publicationMicrofluidics and Nanotechnology
Subtitle of host publicationBiosensing to the Single Molecule Limit
PublisherCRC Press
Pages19-85
Number of pages67
ISBN (Electronic)9781466594913
ISBN (Print)9781466594906
DOIs
StatePublished - Jan 1 2017

Fingerprint

Biochips
genome
Human Genome
sequencing
Assays
CMOS
DNA
deoxyribonucleic acid
Genes
Human Genome Project
Genome
Technology
Costs and Cost Analysis
Precision Medicine
Private Sector
Public Sector
Firearms
Biotechnology
Genomics
Base Pairing

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Engineering(all)
  • Physics and Astronomy(all)

Cite this

Levine, P. M., Gong, P., Levicky, R., & Shepard, K. L. (2017). Active CMOS biochip for electrochemical DNA assays. In Microfluidics and Nanotechnology: Biosensing to the Single Molecule Limit (pp. 19-85). CRC Press. https://doi.org/10.1201/b17020

Active CMOS biochip for electrochemical DNA assays. / Levine, Peter M.; Gong, Ping; Levicky, Rastislav; Shepard, Kenneth L.

Microfluidics and Nanotechnology: Biosensing to the Single Molecule Limit. CRC Press, 2017. p. 19-85.

Research output: Chapter in Book/Report/Conference proceedingChapter

Levine, PM, Gong, P, Levicky, R & Shepard, KL 2017, Active CMOS biochip for electrochemical DNA assays. in Microfluidics and Nanotechnology: Biosensing to the Single Molecule Limit. CRC Press, pp. 19-85. https://doi.org/10.1201/b17020
Levine PM, Gong P, Levicky R, Shepard KL. Active CMOS biochip for electrochemical DNA assays. In Microfluidics and Nanotechnology: Biosensing to the Single Molecule Limit. CRC Press. 2017. p. 19-85 https://doi.org/10.1201/b17020
Levine, Peter M. ; Gong, Ping ; Levicky, Rastislav ; Shepard, Kenneth L. / Active CMOS biochip for electrochemical DNA assays. Microfluidics and Nanotechnology: Biosensing to the Single Molecule Limit. CRC Press, 2017. pp. 19-85
@inbook{950440e9714042f388a7a7c6950e1e5e,
title = "Active CMOS biochip for electrochemical DNA assays",
abstract = "20 21The development of methods and technology to perform genome sequencing and genomic assays has enabled significant advances in biomedical research in the past and will have a profound impact on the areas of disease prevention, personalized medicine, and clinical diagnostics in the future [1]. Over the last two decades, enormous effort from the public and private sectors has been spent on “sequencing” the human genome; that is, determining the exact series of the approximately 6 billion nucleotide base pairs contained in the 46 chromosomes found in most human cells. Ever since drafts of the human genome were first published in 2001 by both the publicly funded International Human Genome Sequencing Consortium through the Human Genome Project (HGP) [2] and a team led by J. Craig Venter of the privately owned biotechnology company Celera Genomics [3], the cost of human genome sequencing has declined by many orders of magnitude due to the introduction of increasingly automatable methods and technology. In particular, shotgun sequencing approaches [4] involving dideoxy chain termination techniques and electrophoretic size separation (known as “Sanger sequencing,” after the individual who developed the technique [5]) have been replaced by massively parallel optical [6,7] and electronic [8] sequencing-by-synthesis platforms. These innovations have brought the cost of human genome sequencing down from US$3 billion, in the case of the HGP [9], to well under US$1 million [8]. Further technological developments will undoubtedly occur until one’s own genome can be sequenced for less than US$1000 [10].",
author = "Levine, {Peter M.} and Ping Gong and Rastislav Levicky and Shepard, {Kenneth L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1201/b17020",
language = "English (US)",
isbn = "9781466594906",
pages = "19--85",
booktitle = "Microfluidics and Nanotechnology",
publisher = "CRC Press",

}

TY - CHAP

T1 - Active CMOS biochip for electrochemical DNA assays

AU - Levine, Peter M.

AU - Gong, Ping

AU - Levicky, Rastislav

AU - Shepard, Kenneth L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - 20 21The development of methods and technology to perform genome sequencing and genomic assays has enabled significant advances in biomedical research in the past and will have a profound impact on the areas of disease prevention, personalized medicine, and clinical diagnostics in the future [1]. Over the last two decades, enormous effort from the public and private sectors has been spent on “sequencing” the human genome; that is, determining the exact series of the approximately 6 billion nucleotide base pairs contained in the 46 chromosomes found in most human cells. Ever since drafts of the human genome were first published in 2001 by both the publicly funded International Human Genome Sequencing Consortium through the Human Genome Project (HGP) [2] and a team led by J. Craig Venter of the privately owned biotechnology company Celera Genomics [3], the cost of human genome sequencing has declined by many orders of magnitude due to the introduction of increasingly automatable methods and technology. In particular, shotgun sequencing approaches [4] involving dideoxy chain termination techniques and electrophoretic size separation (known as “Sanger sequencing,” after the individual who developed the technique [5]) have been replaced by massively parallel optical [6,7] and electronic [8] sequencing-by-synthesis platforms. These innovations have brought the cost of human genome sequencing down from US$3 billion, in the case of the HGP [9], to well under US$1 million [8]. Further technological developments will undoubtedly occur until one’s own genome can be sequenced for less than US$1000 [10].

AB - 20 21The development of methods and technology to perform genome sequencing and genomic assays has enabled significant advances in biomedical research in the past and will have a profound impact on the areas of disease prevention, personalized medicine, and clinical diagnostics in the future [1]. Over the last two decades, enormous effort from the public and private sectors has been spent on “sequencing” the human genome; that is, determining the exact series of the approximately 6 billion nucleotide base pairs contained in the 46 chromosomes found in most human cells. Ever since drafts of the human genome were first published in 2001 by both the publicly funded International Human Genome Sequencing Consortium through the Human Genome Project (HGP) [2] and a team led by J. Craig Venter of the privately owned biotechnology company Celera Genomics [3], the cost of human genome sequencing has declined by many orders of magnitude due to the introduction of increasingly automatable methods and technology. In particular, shotgun sequencing approaches [4] involving dideoxy chain termination techniques and electrophoretic size separation (known as “Sanger sequencing,” after the individual who developed the technique [5]) have been replaced by massively parallel optical [6,7] and electronic [8] sequencing-by-synthesis platforms. These innovations have brought the cost of human genome sequencing down from US$3 billion, in the case of the HGP [9], to well under US$1 million [8]. Further technological developments will undoubtedly occur until one’s own genome can be sequenced for less than US$1000 [10].

UR - http://www.scopus.com/inward/record.url?scp=85054242801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054242801&partnerID=8YFLogxK

U2 - 10.1201/b17020

DO - 10.1201/b17020

M3 - Chapter

AN - SCOPUS:85054242801

SN - 9781466594906

SP - 19

EP - 85

BT - Microfluidics and Nanotechnology

PB - CRC Press

ER -